Jul. 23 at 4:01 PM
$MAIA Phase 2B had great data, but it was convoluted due to the mixing and matching of doses, 2L, and 3L patients.
Phase 2C is as clear as day:
1) 180mg dose
2) 3L patients
3) 19/21 patients have achieved disease control.
This is PHENOMENAL, and has a high chance of extending OS far above the current Standard of Care. The market is completely mispricing MAIA right now, which leaves those of us paying attention with a great deal to load up! 💰 The scientific risk of MAIA is collapsing and the intrinsic value of MAIA is rising. 📈
